Journal of Virology · 1998 · 134 citations · 51 references
Life SciencesGeneticsMolecular GeneticsMedical GeneticsMolecular VirologyVirologyAntiviral TherapyInterferon ResponsesViral GeneticsViral GenomicsViral HepatitisViral MutationGenetic Mutation FrequencyHepatitis C GenotypesHepatitis C InfectionHepatitis C Virus GenotypeHypervariable Region AnalysisInterferon Alfa TherapyMobility RatioMutation
To study hepatitis C virus (HCV) genetic mutation during interferon (IFN) therapy, the temporal changes in HCV quasispecies heterogeneity were compared before and after treatment for nine patients infected with HCV genotype 1, including four nonresponders, four responders who relapsed after therapy, and one responder who experienced a breakthrough of viremia during therapy. Nine untreated patients with an average time between specimens of 8.4 years served as controls. Sequences from the second envelope glycoprotein gene hypervariable region 1 (HVR1) and the putative IFN sensitivity-determining region (ISDR) of the nonstructural NS5A gene were analyzed by heteroduplex mobility assays and nucleotide sequencing. A strong positive correlation was found between the percent change in a heteroduplex mobility ratio (HMR) and percent change in nucleotide sequence (r = 0.941, P < 0.001). The rate of fixation of mutations in the HVR1 was significantly higher for IFN-treated patients than for controls (6.97 versus 1.31% change in HMR/year; P = 0.02). Similarly, a higher rate of fixation of mutations was observed in the ISDR for IFN-treated patients than for untreated controls, although the result was not significant (1.45 versus 0.15 amino acid changes/year; P = 0.12). On an individual patient basis, IFN therapy was associated with measurable HVR1 and ISDR mutation in nine of nine (100%) and two of nine (22.2%) patients, respectively. Evolution to IFN-resistant ISDR sequences was observed in only one of nine IFN-treated patients. These data suggest that IFN therapy frequently exerts pressure on the HCV envelope region, while pressure on the ISDR was evident in only a subset of patients. Thus, the selection pressures evoked on HCV genotype 1 quasispecies during IFN therapy appear to differ among different patients.
51
Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome
Qui‐Lim Choo, George Kuo, Amy J. Weiner et al. · Science · 1989 · 6.9K citations
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Gary L. Davis, Luis A. Balart, Eugene R. Schiff et al. · New England Journal of Medicine · 1989 · 1.7K citations
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Adrian M. Di Bisceglie, Paul Martin, Chris Kassianides et al. · New England Journal of Medicine · 1989 · 1.2K citations